The lymphocyte-to-monocyte ratio could predict the efficacy of PD-1 inhibitors in patients with advanced cancer
Open Access
- 1 July 2020
- journal article
- research article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 9 (7) , 4111-4120
Abstract
Background: PD-1/PD-L1 inhibitors have made remarkable achievements in the field of tumor treatment. However, most patients do not benefit from PD-1/PD-L1 inhibitor therapy, and some patients experience adverse reactions. Therefore, finding ideal prognostic indicators to predict the efficacy of PD-1/PD-L1 inhibitors and selecting populations that can potentially benefit clinically are crucial. The purpose of this retrospective analysis was to investigate the prognostic value of the lymphocyte-to-monocyte ratio (LMR) in patients with advanced tumors using PD-1 inhibitors to identify patients who may have a better response to PD-1 inhibitors. Methods: The clinical data of 121 patients with advanced cancer at the Affiliated Tumor Hospital of Zhengzhou University were retrospectively analyzed. The receiver operating characteristic (ROC) curve was used to determine the best cutoff value of the LMR, and subsequently, the patients were divided into high- and low-LMR groups. Kaplan-Meier and log-rank tests were used to draw survival curves. Univariate and multivariate analyses used Cox proportional hazard regression models to assess the association between the LMR and overall survival (OS) or progression-free survival (PFS). Results: The ROC curve showed that the areas under the curve at baseline and 6 weeks after anti-PD-1 antibody treatment LMR (LMR-week 1 and LMR-week 6, respectively) were 0.593 (P=0.164) and 0.713 (P=0.002), respectively. The optimal cutoff value of LMR-week 6 was 4.15, and in a total of 121 patients, 66 and 55 presented with LMR-week 6 Conclusions: LMR-week 6 is significantly related to the effect of anti-PD-1 antibody treatment; therefore, LMR-week 6 can be used as an early surrogate indicator for stratification in patients who respond better to anti-PD-1 drugs.Keywords
This publication has 30 references indexed in Scilit:
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- Tumor-Associated Macrophages as Major Players in the Tumor MicroenvironmentCancers, 2014
- Inflammation lights the way to metastasisNature, 2014
- Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinomaWorld Journal of Surgical Oncology, 2014
- Tumor-Infiltrating Immune Cells Promoting Tumor Invasion and Metastasis: Existing TheoriesJournal of Cancer, 2013
- Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag levelGynecologic Oncology, 2012
- Immunity, Inflammation, and CancerCell, 2010
- Cancer-related inflammationNature, 2008
- Inflammation and cancerNature, 2002
- Inflammation and cancer: back to Virchow?The Lancet, 2001